Gilead's Remdesivir prevented lung disease in macaque monkeys infected with coronavirus: Study

The antiviral drug, Remdesivir is the first drug shown to be effective against COVID-19 in human trials.

|Jun 10, 2020, 10:25:14 IST

Gilead Sciences Inc’s antiviral drug remdesivir prevented lung disease in macaque monkeys infected with the new coronavirus, according to a study published in the journal Nature on Tuesday.The findings were first reported in April by the U.S. National Institutes of Health (NIH) as a “preprint,” prior to traditional academic validation provided by a medical journal.Remdesivir is the first drug shown to be effective against COVID-19 in human trials. Other clinical studies involving the drug are being closely watched as nations look for treatments for the disease that has infected more than 7 million people and killed over 400,000 globally.[caption id="attachment_8467761" align="alignnone" width="1280"]

Remdesivir prevented lung disease in macaque monkeys infected with the new coronavirus,[/caption]Remdesivir was approved last month in Japan under the brand name Veklury. It has been cleared for emergency use in severely-ill patients in the United States, India and South Korea. Some European nations are also using it under compassionate programs.In the study published on Tuesday, 12 monkeys were infected with the new coronavirus, and half of them were given early treatment with remdesivir.Macaques that received remdesivir did not show signs of respiratory disease and had reduced damage to the lungs.Authors of the study also said the viral load, or amount of virus, in the lungs of remdesivir-treated animals was lower.The authors suggested that remdesivir should be considered as a treatment as early as possible to prevent progression to pneumonia in COVID-19 patients.In a U.S.-run clinical trial released in late April, remdesivir reduced hospitalization stays by 31%, or about four days, compared to a placebo.Gilead last week reported data from its own trial of remdesivir, showing that the drug provided a modest benefit for patients with moderate COVID-19 given a five-day course of the treatment.

Stroke is rising among young adults. Doctor explains why it's happening and what you must do

Stroke is increasingly affecting adults in their 30s, 40s and 50s. Experts say unhealthy lifestyles, undiagnosed high blood pressure and delayed treatment are driving the rise in younger stroke cases

3 min read

Stroke in young adults, silent symptoms and late diagnosis: India's growing brain health challenge

Neurologists warn that stroke is increasingly affecting people in their 30s and 40s, while many brain disorders progress silently before symptoms appear. They say early diagnosis, timely referrals and healthier lifestyles are key to reducing India's growing neurological disease burden.

5 min read

Brain tumours aren't always fatal, but delayed diagnosis can be: Experts explain the key warning signs

Brain tumours are frequently mistaken for common headaches, stress or age-related cognitive changes. Doctors say recognising warning signs early and adopting a brain-healthy lifestyle can improve outcomes and reduce the risk of long-term neurological complications.

2 min read

Spices, health and the Indian plate: Why chilli can be good for you—but moderation is still key

From boosting metabolism to supporting heart health, chillies offer several surprising health benefits. But experts say the amount you eat matters, and too much spice can do more harm than good.

4 min read

Organ donation: 5 myths you need to stop believing, according to a transplant specialist

Organ donation has the power to transform and save lives, but this can happen only when myths are replaced with facts. Building awareness, having open conversations and understanding the process can help families make informed decisions.